NCT05118360View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 1, 2023

Primary Completion Date

November 10, 2024

Study Completion Date

January 9, 2025

Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
DRUG

ASC41 2 mg

2mg of ASC41 orally once daily for 52 weeks

DRUG

ASC41 4 mg

4mg of ASC41 orally once daily for 52 weeks

DRUG

Placebo

Matching placebo orally once daily for 52 weeks.

Sponsors
All Listed Sponsors
lead

Gannex Pharma Co., Ltd.

INDUSTRY